CoChat

One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma

Open access
Park, So Hee, Kim, Myung Ji, Jung, Hyun Ho, Chang, Won Seok, Choi, Hyun Seok, Rachmilevitch, Itay, Zadicario, Eyal, Chang, Jin Woo · 2020 · Frontiers in Oncology
Cited by 98

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Introduction : To overcome the blood-brain barrier (BBB) which interferes with the effect of chemotherapeutic agents, we performed multiple disruption of BBB (BBBD) with magnetic resonance-guided focused ultrasound (MRgFUS) on patients with glioblastoma (GBM) during standard adjuvant temozolomide (TMZ) chemotherapy. We report a one-year follow-up result of BBBD with TMZ for GBM. Methods: From September 2018 to January 2019, six patients were enrolled (4 men and 2 women, mean age: 55.83±11.03 years). Of the six patients, five underwent a total of 6 cycles of BBBD during standard TMZ adjuvant therapy. One patient underwent 3 cycles of BBBD but continued with TMZ chemotherapy. The one-year follow-up results of these 6 patients were reviewed. Results: The mean follow-up duration was 15.17±1.72 months. Two patients showed recurrence of tumor at 11 months and 16 months, respectively. One underwent surgery, and the other patient was restarted with TMZ chemotherapy due to the tumor location with highly possibility of surgical complications. The survival rate up to 1 year was 100% and the other four patients are on observation without recurrence. None of the six patients had immediate or delayed BBBD-related complications. Conclusion: Multiple BBBDs can be regarded as a safe procedure without long-term complication and it seems to have some survival benefits. However, since TMZ partially crosses the BBB, further extended study with large numbers would be needed to evaluate the benefits of BBBD resulting in an increase of TMZ concentration. This study opened a new therapeutic strategy for GBM by combining BBBD with a therapeutic agent which could not be used due to BBB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2020.01663

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 98

Metadata

Authors
Park, S. H., Kim, M. J., Jung, H. H., Chang, W. S., Choi, H. S., Rachmilevitch, I., Zadicario, E., & Chang, J. W.
Venue
Frontiers in Oncology
Published
2020-09-10
Volume
10
Pages
1663-1663
ISSN
2234-943X (ISSN-L)
OpenAlex
W3084799131
Cited by
98
References
3
FWCI
4.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.